CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...
Phase 3
Atlanta, Georgia, United States and 66 other locations
The primary objective of this study is to characterize the safety and tolerability of loncastuximab tesirine in combination with polatuzumab vedotin,...
Phase 1
Atlanta, Georgia, United States and 34 other locations
at different dosages in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). Cem...
Phase 1, Phase 2
Atlanta, Georgia, United States and 12 other locations
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non...
Phase 1
Atlanta, Georgia, United States and 34 other locations
This phase II trial studies the effect of acalabrutinib and obinutuzumab in treating patients with follicular lymphoma or other indolent non...
Phase 2
Atlanta, Georgia, United States
given together with obinutuzumab in treating patients with B-cell non-Hodgkin lymphoma that has returned after a period of...
Phase 1
Atlanta, Georgia, United States and 1 other location
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purp-...
Phase 2
Atlanta, Georgia, United States and 74 other locations
CLN-978-001 is a Phase 1, open-label, dose escalation and dose expansion study of CLN-978 in patients with Relapse/Refractory (R/R) B-cell Non...
Phase 1
Atlanta, Georgia, United States and 5 other locations
clinical trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two...
Phase 1, Phase 2
Atlanta, Georgia, United States and 20 other locations
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab in Subjects with Indolent B-Cell Non...
Phase 1, Phase 2
Atlanta, Georgia, United States and 21 other locations
Clinical trials
Research sites
Resources
Legal